Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop
synthetic biology systems, today announced the commercial launch of
its BioXp™ mRNA synthesis kits with CleanCap® Reagent AG, a
proprietary mRNA capping technology from TriLink BioTechnologies,
part of Maravai LifeSciences (NASDAQ: MRVI). These new automation
kits will allow users to generate large yields of high-quality,
capped mRNA to accelerate the discovery and development of
mRNA-based vaccines and therapeutics.
The COVID-19 pandemic has underscored the importance of
efficiently building robust, reliable mRNA-based vaccines and
therapies. Existing manual, multi-step mRNA synthesis processes
often result in long turnaround timelines and cause significant
bottlenecks during the design-build-test phases of discovery and
development, despite the need for rapid iterations of mRNA
constructs.
“We have demonstrated that our industry-leading mRNA capping
technology works seamlessly within Codex DNA’s mRNA synthesis kit,”
said Jeff Whitmore, Vice President of Commercial Operations at
TriLink BioTechnologies. “The combination of our CleanCap
technology with the fully automated, benchtop BioXp system will
empower scientists to drive efficiency in the discovery and
development of mRNA-based interventions.”
BioXp kits with integrated CleanCap Reagent AG are designed to
increase the productivity and efficiency of mRNA synthesis
workflows. Codex DNA customers are now able to generate up to 16
biologically active mRNA constructs at a median yield of 10
micrograms each from fully de novo synthesized and error-corrected
genes in a single automated run. The increased proportion of
translationally active mRNA simplifies and shortens the mRNA
manufacturing process, resulting in higher levels of protein
production.
Todd R. Nelson, PhD, CEO of Codex DNA, commented: “Our
commitment to automated, high-quality mRNA synthesis has
significantly reduced the time required to produce these critical
components for candidate vaccines and therapeutics. We believe the
addition of CleanCap technology to our kits will continue to
accelerate the discovery process and help scientists get
much-needed new treatments to market faster.”
Key Educational Conferences Focus on Promise of
mRNA-based Vaccines
Two upcoming events will feature new developments in mRNA-based
treatments for scientists, reporters, and other interested
parties.
mRNA Applications in Discovery &
DevelopmentNovember 30, 2021 – December 2, 2021Codex DNA
Director of R&D Krishna Kannan will give a presentation titled
“Sequence in, mRNA out. A new paradigm to accelerate discovery of
mRNA vaccines and therapeutics” on November 30, 2021, at 11:00 AM
EST / 8:00 AM PST.
TriLink BioTechnologies Application Scientist (mRNA) Cory Smith
will give a presentation titled “Fine-Tuning mRNA Fate and
Function: Modified Uridine as a Therapeutic Tool” on December 1,
2021, at 11:00 am EST / 8:00 AM PST.
World Vaccine & Immunotherapy
CongressNovember 30, 2021 – December 2, 2021Loews Coronado
Bay ResortSan Diego, CA
Codex DNA representatives will be at booth #13 to highlight the
BioXp 3250 system and BioXp mRNA synthesis kit with CleanCap
technology.
About TriLink BioTechnologies
TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO
helping life science leaders and innovators overcome challenges in
the synthesis and scale-up of nucleic acids, NTPs, and mRNA capping
analogs with scale-up expertise and unique mRNA production
capabilities, including its proprietary CleanCap® mRNA capping
technology. TriLink continues to expand its GMP and general
manufacturing capacity at its new global headquarters in San Diego
California to support mRNA, oligonucleotide, and plasmid
therapeutic, vaccine, and diagnostic
customers. www.trilinkbiotech.com
About Maravai LifeSciencesMaravai is a leading
life sciences company providing critical products to enable the
development of drug therapies, diagnostics, novel vaccines, and
support research on human diseases. Maravai’s companies are leaders
in providing products and services in the fields of nucleic acid
synthesis, and bioprocess impurity detection and analysis to many
of the world's leading biopharmaceutical, vaccine, diagnostics, and
cell and gene therapy companies. For more information about Maravai
LifeSciences, visit www.maravai.com.
About Codex DNA
Codex DNA is empowering scientists with the ability to create
novel, synthetic biology-enabled solutions for many of humanity’s
greatest challenges. As inventors of the industry-standard Gibson
Assembly® method and the first commercial automated benchtop DNA
and mRNA synthesis system, Codex DNA is enabling rapid, accurate,
and reproducible writing of DNA and mRNA for numerous downstream
markets. The company’s award-winning BioXp™ system consolidates,
automates, and optimizes the entire synthesis, cloning, and
amplification workflow. As a result, it delivers virtually
error-free synthesis of DNA/RNA at scale within days and hours
instead of weeks or months. Scientists around the world are using
the technology in their own laboratories to accelerate the
design-build-test paradigm for novel, high-value products for
precision medicine, biologics drug discovery, vaccine and
therapeutic development, genome editing, and cell and gene therapy.
Codex DNA is a public company based in San Diego. For more
information, visit codexdna.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on
Codex DNA’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Codex DNA’s actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. These
statements include but are not limited to statements regarding
Codex DNA’s ability to successfully integrate in a commercial
setting the CleanCap® mRNA capping technology with its BioXp™ and
the combination’s ability to improve the research process for
organizations. These and other risks are described more fully in
Codex DNA’s filings with the Securities and Exchange Commission
(“SEC”) and other documents that Codex DNA subsequently files with
the SEC from time to time. Except to the extent required by law,
Codex DNA undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Contact:Richard LepkeDirector of Investor Relations(619)
840-5392RichardL@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jul 2023 to Jul 2024